Metabolic reprogramming in breast cancer: Pathways driving progression, drug resistance, and emerging therapeutics
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2025-10 · 1880 (5) · 189396
DOI: 10.1016/j.bbcan.2025.189396 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025-10. Verfasst von Pankaj Garg und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, GLA University, Mathura, Uttar Pradesh 281406, India. Hauptthemen laut MEDLINE: Breast Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, National Cancer Institute.
Abstract (Originalsprache)
Breast cancer (BC), one of the most frequent causes of cancer-related death in women, is known to be a highly heterogeneous disease in regard to molecular subtypes, which seem to possess different metabolic profiles. Aberrant metabolism is well understood as one of the hallmarks of cancer and it contributes to BC progression, therapeutic resistance, and metastasis. Here, we analyze BC metabolism and how certain cancer types, such as hormone receptor-positive, HER2-positive, and triple-negative BC, use glycolysis, lipid metabolism, amino acid compulsion, and mitochondrial biogenesis to feed and proliferate. These metabolic hallmarks, in the context of the tumor microenvironments, are illustrated to highlight the metabolic byproducts that are derived from reprogrammed pathways and are vital to immunosuppression and tumor survival under low oxygen and nutrient availability. Furthermore, we emphasize novel trends in anticancer drugs designed to strike on these metabolic dependencies to suppress tumor growth. In addition to summing up current knowledge about metabolic reprogramming in BC, this review reveals new targets for specific treatments that might enhance prognosis in certain types of BC. This review aims to bridge basic scientific insights and clinical perspectives, guiding future metabolic interventions in BC toward clinically relevant, subtype-specific therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, GLA University, Mathura, Uttar Pradesh 281406, India.
- Undergraduate Medical Sciences, S.N. Medical College, Agra, Uttar Pradesh 282002, India.
- Departments of Molecular Medicine, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA 91010, USA.
- Department of Medical Oncology & Therapeutics Research, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA 91010, USA.
- Department of Medical Oncology & Therapeutics Research, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA 91010, USA. Electronic address: ssinghal@coh.org.
Förderung
- NCI NIH HHS
- National Institutes of Health
- National Cancer Institute
- Beckman Research Institute, City of Hope
- US Department of Defense
Zitieren
APA
Garg, P., Singhal, G., Horne, D., Salgia, R., & Singhal, S. S. (2025). Metabolic reprogramming in breast cancer: Pathways driving progression, drug resistance, and emerging therapeutics. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1880(5), 189396. https://doi.org/10.1016/j.bbcan.2025.189396
Vancouver
Garg P, Singhal G, Horne D, Salgia R, Singhal SS. Metabolic reprogramming in breast cancer: Pathways driving progression, drug resistance, and emerging therapeutics. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2025;1880(5):189396. doi:10.1016/j.bbcan.2025.189396
BibTeX
@article{Garg2025,
author = {Garg, Pankaj and Singhal, Gargi and Horne, David and Salgia, Ravi and Singhal, Sharad S},
title = {Metabolic reprogramming in breast cancer: Pathways driving progression, drug resistance, and emerging therapeutics},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2025},
volume = {1880},
number = {5},
pages = {189396},
doi = {10.1016/j.bbcan.2025.189396}
}
EUVIMED